LX9851
LX9851 is an investigational oral obesity medicine from Lexicon Pharmaceuticals, now developed by Novo Nordisk. It is not a GLP-1 drug. It is in an early safety trial, and no human weight-loss results are public. It is not approved.
Also searched as: LX 9851, Lexicon ACSL5 inhibitor, Novo Nordisk oral ACSL5 inhibitor, non-GLP-1 obesity pill. Updated November 8, 2026.
Quick answer. LX9851 is a pill that blocks an enzyme in the gut called ACSL5. Lexicon Pharmaceuticals found it, and Novo Nordisk holds worldwide rights. A phase 1 safety trial in 96 adults with overweight or obesity began in March 2026 and is due to finish in the first quarter of 2027. The only efficacy information is from mice, and no numbers were released. No dose has been published, and it is not approved.
Educational information. This page does not give dosing instructions or tell you what to take. Ask a prescriber about your own care.
In plain English
Most weight-loss medicines you hear about copy a gut hormone. Wegovy and Zepbound work mainly on GLP-1, and some add other hormones. LX9851 takes a different route. It is a pill that blocks an enzyme called ACSL5 in the lining of the intestine. Lexicon calls it a first-in-class, non-incretin medicine, which means it is not trying to copy GLP-1 or GIP.
Lexicon Pharmaceuticals, a Texas company, discovered it. In March 2025 it gave Novo Nordisk, the maker of Wegovy, an exclusive license to develop and sell it worldwide. Novo Nordisk started the first human trial in March 2026.
This is very early. A phase 1 trial asks whether a medicine is safe and how the body handles it. It is not built to prove weight loss.
LX9851 at a glance
| Question | Answer |
|---|---|
| What is the code? | LX9851, a development code from Lexicon Pharmaceuticals. It has no brand name and no generic name. |
| Is it a peptide? | No. It is described as a small-molecule pill, not a peptide. |
| Who is developing it? | Novo Nordisk, under an exclusive worldwide license from Lexicon signed in March 2025. |
| How is it taken? | By mouth. |
| What does it target? | ACSL5, an enzyme found in the intestine. It does not act on the GLP-1 receptor. |
| What stage is it in? | Phase 1: single and multiple rising doses against placebo in 96 adults with overweight or obesity. It started in March 2026 and is expected to finish in the first quarter of 2027. |
| Is there a published dose? | No. The companies have not said what amounts are being tested. |
| Is it approved? | No. It is not approved anywhere. |
How it is meant to work
Your small intestine has a built-in fullness signal called the ileal brake. When food, especially fat, reaches the last part of the small intestine, the gut sends signals that slow the stomach and turn down appetite. Gut hormones such as GLP-1 and PYY are part of that message.
Lexicon's idea is that blocking ACSL5 may trigger this brake earlier and more strongly. The company's own wording is careful: the medicine "may" activate it. In mice, Lexicon reported that removing the ACSL5 gene, or treating mice with the pill, reduced how much high-fat food they ate, and it linked that to the ileal brake.
What has been shown
Everything below about efficacy comes from mice. Lexicon described the results at a conference in November 2024 and did not release numbers.
| Stage | What is known |
|---|---|
| Mice, alone | Lower body weight and food intake in diet-induced obese mice. No percentages were released. |
| Mice, with semaglutide | Additive weight loss when combined with semaglutide, with lean mass not significantly affected. Fat mass on a day 28 scan was lower in every LX9851 group. |
| Mice, after stopping semaglutide | Less weight regain than in comparison groups, according to Lexicon. |
| Mice, liver fat | Additive benefit on liver fat when combined with semaglutide. |
| People | A phase 1 trial started in March 2026. No results are public. |
| The deal | Novo Nordisk has paid Lexicon milestone payments tied to the trial. Lexicon reported $75 million earned in total as of November 5, 2026, out of up to $1 billion plus royalties. That shows commitment, not results. |
What is confirmed and what is only reported
Confirmed in company releases
- Lexicon discovered LX9851, and Novo Nordisk holds worldwide rights.
- It is an oral ACSL5 inhibitor described as non-incretin.
- The phase 1 trial runs in 96 adults with overweight or obesity and began in March 2026.
- Completion is expected in the first quarter of 2027.
Reported but not backed by company data
- A "10 to 15 percent weight loss" figure in a video summary. It is not in any Lexicon release and has not been shown in people.
- Claims that it needs no gradual dose increase. The trial is raising doses on purpose, so this is unknown.
- A launch date such as "2030 or later." This was one commentator's guess.
How LX9851 differs from GLP-1 medicines
Semaglutide and tirzepatide copy hormones the gut already makes. LX9851 would instead block an enzyme and let the gut signal itself. That is why researchers are interested in using it alongside a GLP-1 medicine, as the mouse work tested. It is also why nothing about GLP-1 side effects, dosing or results can be assumed for it. For the formats people use today, see GLP-1 pill or shot. For why weight often returns after stopping, see weight regain after stopping.
How to read an early trial
A phase 1 trial is small and short. It tells you whether the first people who took the medicine did well, and what dose range is reasonable to test next. It does not tell you how much weight anyone will lose. Mouse results are an even earlier signal and often shrink in people. Treat every efficacy claim about LX9851 as unproven until a phase 2 trial reports.
If you see LX9851 for sale
LX9851 has no approved product. Anyone selling it as a pill, powder or injection is not selling a tested medicine, and what is in the product cannot be checked against anything. The only legitimate way to receive it today is inside Novo Nordisk's trial.
What would change the picture
- Phase 1 results that show safe, tolerable dosing in people.
- A phase 2 trial that measures weight loss against placebo.
- Any human data on combining it with a GLP-1 medicine.
- A peer-reviewed paper on the mouse studies, with numbers.
What is still unknown
- How much weight, if any, it helps people lose.
- The dose, how often it would be taken, and whether it needs gradual increases.
- Its safety and side effects in people.
- Whether it works alone or only alongside a GLP-1 medicine.
- The trial's registry listing. We could not match it to a ClinicalTrials.gov record, so no trial ID is given.
Quick answers
- What is LX9851?
- LX9851 is an investigational oral obesity medicine discovered by Lexicon Pharmaceuticals and developed by Novo Nordisk. It blocks the ACSL5 enzyme and is not a GLP-1 drug.
- Is LX9851 a GLP-1 medicine?
- No. It does not act on the GLP-1 receptor. Lexicon calls it non-incretin.
- Has LX9851 been tested in people?
- A phase 1 safety trial in 96 adults with overweight or obesity began in March 2026. No results are public.
- How much weight does LX9851 cause people to lose?
- Nobody knows yet. The only data are from mice, and no numbers were released.
- What is the LX9851 dose?
- No dose has been published.
- Is LX9851 approved?
- No. It is not approved anywhere.
- When could LX9851 be available?
- No company has given a date. The phase 1 trial is due to finish in the first quarter of 2027, and Novo Nordisk decides next steps after that.
- Where can I read more?
- PeptideBlog has a longer research write-up of LX9851, with the mouse data and the unverified claims explained.
Sources
- Lexicon Pharmaceuticals and Novo Nordisk announce initiation of Phase 1 study with oral obesity drug candidate LX9851 Lexicon Pharmaceuticals news release, March 23, 2026. Company announcement
- Lexicon Pharmaceuticals, preclinical in vivo efficacy data for LX9851 at ObesityWeek 2024 Lexicon investor news release, November 4, 2024. Mouse data described without numbers. Company announcement
- Lexicon Pharmaceuticals third quarter 2026 results and clinical update Lexicon investor news release, November 5, 2026. Milestone payments and program status. Company announcement
- LX9851 research write-up PeptideBlog, November 2026. Longer summary with evidence tiers. Research summary